Expression of p53 and RB proteins in squamous cell carcinoma of the esophagus: Their relationship with clinicopathologic characteristics

Annals of Surgical Oncology

Volumn 6, Issue 5, 1999, Pages 489-494

  Hashimoto, Naoki ^a   Tachibana, Mitsuo ^a   Dhar, Dipok K ^a   Yoshimura, Hiroshi ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; P53; Prognosis; Retinoblastoma (RB)

Indexed keywords

PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR DIFFERENTIATION;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032770327     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-999-0489-2     Document Type: Article

References (44)

1. Levine AJ, Monand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
2. Lane DP, Crawford LV. T-antigen is bound to a host protein in SV40 transformed cells. Nature 1979;278:261-3.
3. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-93.
4. Ullich SJ, Anderson CW, Mercer WE, Apella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992;267:15259-62.
5. Oren O. p53: the ultimate tumor suppressor gene? FASEB J 1992; 6:3169-76.
6. Chang F, Syrjanen S, Kurvianen K, Syrjanen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993;88:174-6.
7. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244:217-20.
8. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;246:491-4.
9. Varley JM, Brammer WJ, Lane DP, Swallow JE, Dolan C, Walker RA. Loss of chromosome 17p3 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991;6:413-21.
10. Marks JR, Devidoff AM, Kerns BJ, et al. A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51: 2979-84.
11. Sidransky D, Mikkelsen T, Schwecheleimer K, Rosenblum ML, Cavanee W, Vogelstein B. Clonal expansion of p53 mutant cell is associated with brain tumor progression. Nature 1992;355:846-7.
12. Hsu IC, Metkalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
13. Bressac B, Kew M, Wands L, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature 1991;350:429-31.
14. Fenaux P, Jonveaux P, Quiquandon I, et al. p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991;78: 1652-7.
15. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-9.
16. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B, Roth JA. Oncogene activation in esophageal cancer. J Thorac Cardiovasc Surg 1991;102:707-9.
17. Ono H, Takahashi A, Ogoshi S, Furihata M, Ohtsuki Y. Relationship between H-ras p21 product and p53 protein or high-risk-human papillomaviruses in esophageal cancer from Kochi, Japan. Am J Gastroenterol 1994;89:646-7.
18. Chang F, Syrjanen S, Tervahauta A, Kurvinen K, Wang L, Syrjanen K. Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis. Br J Cancer 1994;70:346-51.
19. Hollstein MC, Peri L, Mandard AM, et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: Frequent p53 base substitutions and absence of ras mutations. Cancer Res 1991;51:4102-6.
20. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 1993;53:846-50.
21. Wang L-D, Hong J-Y, Qiu S-L, Gao H, Yang CS. Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res 1993;53:1783-7.
22. Gao H, Wang L-D, Zhou Q, Hong J-Y, Huang T-Y, Yang CS. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994;54:4342-6.
23. Sasano H, Goukon Y, Nishihira T, Nagura H. In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma. Am J Pathol 1992;141:545-50.
24. DeCaprio JA, Ludlow JW, Figge J, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;54:275-83.
25. Ludlow JW, DeCaprio JA, Huang C-M, Lee W-H, Paucha E, Livingston DM. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 1989;56:57-65.
26. Xu HJ, Hu SX, Benedict WF. Lack of nuclear Rb protein staining in G0/middle G1 cells: correlation to changes in total Rb protein level. Oncogene 1991;6:1139-46.
27. Jiang W, Zhang Y-J, Kahn SM, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 1990;90:9026-30.
28. Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-9.
29. Goodrich DW, Wang NP, Quian Y, Lee W-H. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991;67:293-302.
30. Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994;79:573-82.
31. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
32. Wright C, Thomas D, Mellon K, Neal DE, Wilson Horne CH. Expression of retinoblastoma and p53 protein in bladder carcinoma: correlation with Ki 67 index. Br J Urol 1995;75:173-9.
33. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53, and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4:829-34.
34. Naka T, Toyota N, Kanako T, Kaibara N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998; 18:555-64.
35. Gimenez-Conti IB, Collet AM, Lanfranchi H, et al. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 1996;78:17-23.
36. Beck T, Weller EE, Brumm C, Wilkens C, Knapstein PG. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol 1995;57:96-104.
37. D'Errico A, Grigioni WF, Fiorentino M, Baccarini P. Grazi GL, Mancini AM. Overexpression of p53 protein and Ki67 proliferative index in hepatocellular carcinoma: an immunohistochemical study on 109 Italian patients. Pathol Int 1994;44:682-87.
38. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50:859-62.
39. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
40. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
41. Wang D-Y, Xiang Y-Y, Tanaka M, et al. High prevalence of p53 protein overexpression in patients with esophageal cancer in Linxian, China and its relationship to progression and prognosis. Cancer 1994;74:3089-96.
42. Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE. p53 expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218-23.
43. Vijeyasingam R, Darnton SJ, Allen CA, Billingham C, Matthews HR. Expression of p53 protein in oesophageal carcinoma: clinocopathological correlation and prognostic significance. Br J Surg 1994;81:1623-6.
44. Youssef EM, Matsuda T, Takada N, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995;76:358-66.